- Molecular NameCalcidiol
- SynonymCalcifediol; Calcifediol Anhydrous; Calcifediolum [INN-Latin]; Calcifidiol
- Weight400.647
- Drugbank_IDDB00146
- ACS_NO19356-17-3
- Show 3D model
- LogP (experiment)5.785
- LogP (predicted, AB/LogP v2.0)6.68
- pkaN/A
- LogD (pH=7, predicted)6.68
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-5.98
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds6
- TPSA40.46
- StatusFDA approved
- AdministrationN/A
- PharmacologyA prehormone which is produced by hydroxylation of vitamin D3 (cholecalciferol) in the liver. Calcidiol is then converted in the kidneys (by the enzyme 25(OH)D-1α-hydroxylase) into calcitriol (1,25-(OH)2D3), a secosteroid hormone that is the active form of vitamin D.
- Absorption_valueN/A
- Absorption (description)Readily absorbed.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmCalcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.
- Half life288 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityBone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.
- LD50 (rat)N/A
- LD50 (mouse)N/A